Company intelligence / Profile preview

Osyris

Columbia, Maryland, United States

Ownership: Private
Employees: ~360
Development stage: Other

Overview

Osiris Therapeutics pioneered the development and commercialization of mesenchymal stem cell therapies, notably Prochymal (remestemcel-L, later Ryoncil), which became the first systemically administered stem cell drug globally to receive regulatory clearance for pediatric acute graft-versus-host disease; the company also launched Grafix for wound care, with clinical validation for diabetic foot ulcers. In 2019, Osiris was acquired by Smith & Nephew, and its MSC drug assets (such as Ryoncil) were sold to Mesoblast, which has further advanced clinical development and received additional global regulatory approvals[1][2][3].

Therapeutic areas: GastroenterologyImmunologyEndocrinologyRheumatology
Modalities: Stem cell therapyBioengineered tissue
Industry: Biotech

Partnerships

NovartisGenzymeNuVasiveSmith & Nephew

Beyond the preview

Go deeper on Osyris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osyris.

Explore the full profile